

MolMed winner of sixth edition of the Annual Most Innovative EU Biotech SME Award

Milan (Italy), 23 June 2015 – MolMed S.p.A. (MLM.MI) announces that today it received the prestigious award promoted by EuropaBio Annual Most Innovative EU Biotech SME Award (red biotech) from the European Commissioner for research, science and innovation, Carlos Moedas.

On the occasion of the ceremony, which took place today at the European Parliament in Brussels, Claudio Bordignon, Chairman and CEO of MolMed, commented: *“It is a great acknowledgement for our company that rewards the efforts made in recent years both in terms of innovative achievements and results obtained in the field of research and development in the biomedical area. To be successful at the international level encourages us to pursue a key role in the field of innovation and makes us proud to represent the Italian biotech industry, has enormous potential and strategic value.”*

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes two anti-tumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company’s shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secrp.it

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325

info@molmed.com - www.molmed.com

Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159